Patents by Inventor Paul B. Savage

Paul B. Savage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11286276
    Abstract: Disclosed herein are cationic steroidal antimicrobials (“CSA compounds” or “ceragenins”) and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSA compounds. CSA compounds may be formulated for treating subjects with ailments responsive to CSA compounds, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering CSA compounds.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: March 29, 2022
    Assignee: Brigham Young University
    Inventor: Paul B. Savage
  • Patent number: 11253634
    Abstract: This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: February 22, 2022
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Carl Genberg, Ronald Bracken
  • Publication number: 20210379091
    Abstract: The present disclosure describes compositions and methods for deactivating coronavirus. A method includes providing a deactivation composition including one or more CSA compounds and a carrier, administering the deactivation composition to a subject, and the deactivation composition deactivating coronavirus virions in the subject or coming into contact with the subject. The method can thereby prevent, decrease, or inhibit a coronavirus infection, such as COVID-19, of the subject.
    Type: Application
    Filed: June 7, 2021
    Publication date: December 9, 2021
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Michael C. Moore
  • Publication number: 20210363174
    Abstract: Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of R1-R18, (e.g., R18) includes a terpenyl group attached via an ester or amide linkage and at least one R1-R18, (e.g., R3, R7 and R12) is an amino acid linked to the steroidal backbone by an ester or amide linkage: R18 has the following structure: —R19—(C?O)—X—R20 where R19 is omitted or alkyl, alkenyl, alkynyl, or aryl, X is oxygen or nitrogen, and R20 is a terpenyl group. R3, R7 and R12 have the following structure: R22R23N—R21—(C?O)—X— where R21 is substituted or unsubstituted alkyl, X is oxygen or nitrogen, and R22 and R23 are independently hydrogen, alkyl, alkenyl, alkynyl, or aryl.
    Type: Application
    Filed: May 19, 2021
    Publication date: November 25, 2021
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventor: Paul B. Savage
  • Publication number: 20210361672
    Abstract: The present disclosure describes compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. A treatment composition comprises a CSA compound, a poloxamer, and a carrier. The combination of CSA compound and poloxamer allows higher concentrations of CSA compound to be used. Where such doses would normally disrupt ciliary function, the poloxamer prevents damage to ciliated tissue without inhibiting the antimicrobial effectiveness of the CSA compound.
    Type: Application
    Filed: March 7, 2019
    Publication date: November 25, 2021
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: Carl Genberg, Paul B. Savage
  • Publication number: 20210355155
    Abstract: Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of at least one of R1-R18, (e.g., R3, R7 and R12) is linked to the steroidal backbone by a urethane group: At least one of R1-R18, (e.g., R3, R7 and R12) has the following urethanyl structure: —O—(C?O)—NR19R20 where R19 and R20 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aminoalkyl, aminoalkenyl, aminoalkynyl, or aminoaryl, provided that at least one of R19 or R20 includes an amino group (e.g., R19 is hydrogen and R20 is (C2-C6)aminoalkyl). R18 can have the following structure: —R21—(C?O)—NR22R23 where R21 is omitted or alkyl, alkenyl, alkynyl, or aryl, and R22 and R23 are hydrogen, alkyl, alkenyl, alkynyl, or aryl, provided that at least one of R22 or R23 is not hydrogen.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 18, 2021
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventor: Paul B. Savage
  • Patent number: 10959433
    Abstract: This disclosure relates to sporicidal compositions and uses thereof. The sporicidal compositions include one or more cationic steroidal antimicrobials (CSAs). The sporicidal compositions may be applied to an object to kill or deactivate bacterial spores contacting the sporicidal composition. The object may be a food product, food processing equipment, industrial equipment, or healthcare facility objects. The sporicidal composition may be administered to a subject that has, is suspected to have, or is at risk for an infection associated with spore-forming bacteria.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: March 30, 2021
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventor: Paul B. Savage
  • Publication number: 20200368253
    Abstract: The present disclosure describes compositions and methods for regenerating tissue and/or preventing tissue loss by stimulating stem cells. A method includes providing a treatment composition including one or more CSA compounds and a carrier, applying the treatment composition to a targeted tissue region of a subject, and the treatment composition stimulating tissue regeneration and/or preventing tissue degradation at the targeted region of the subject.
    Type: Application
    Filed: May 21, 2020
    Publication date: November 26, 2020
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Michael C. Moore, Chad S. Beus
  • Patent number: 10676501
    Abstract: A hydrogel polymer includes a ceragenin compound. The ceragenin compound has a hydrophobicity/hydrophilicity that produces a release rate in a range of 0.1-100 ?g/ml for at least 3 days.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: June 9, 2020
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventor: Paul B. Savage
  • Patent number: 10626139
    Abstract: Disclosed herein are cationic steroidal antimicrobials (“CSAs” or “ceragenins”) and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSAs. CSAs may be formulated for treating subjects with ailments responsive to CSAs, including but not limited to treating bacterial infections. Accordingly, some embodiments include formulations and methods of administering CSAs.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: April 21, 2020
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventor: Paul B. Savage
  • Patent number: 10568893
    Abstract: Methods of treating, reducing, or preventing a disease or symptom relating to a disease such as oral mucositis, gingivitis, periodontitis, gastric mucositis, inflammatory fibrosis, gastritis, colitis, ileitis, Crohn's disease, chronic inflammatory intestinal disease, inflammatory bowel syndrome, chronic inflammatory bowel disease, celiac disease, ulcerative colitis, a gastric ulcer, a peptic ulcer, a buccal ulcer, a nasopharyngeal ulcer, an esophageal ulcer, a duodenal ulcer, a gastrointestinal ulcer, an autoimmune disorder, inflammation associated with cancer, cancer treatment, or radiation, and/or pain that include: identifying a patient in need of treatment; and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: February 25, 2020
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Carl Genberg
  • Patent number: 10441595
    Abstract: Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: October 15, 2019
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Carl Genberg, Chad S. Beus, Paul B. Savage
  • Patent number: 10370403
    Abstract: Disclosed herein are methods of making ceragnenin compounds for treating, preventing, or diagnosing diseases, disorders, or conditions associated with bacterial or viral infections, cancer, inflammation, and osteogenesis. Ceragenin compounds display broad-spectrum antibacterial activity utilizing a mode of action similar to antimicrobial peptides, but without the high synthesis costs and susceptibility to proteolytic degradation. Ceragenin compounds reproduce the amphiphilic morphology found in many antimicrobial peptides and display potent and diverse biological activities, including anti-bacterial, anti-cancer, anti-inflammatory, bone growth promotion, and wound healing promotion.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: August 6, 2019
    Assignee: Brigham Young University
    Inventors: Paul B. Savage, Thomas E. Jacks, Ross A. Miller, Andrew S. Thompson, Jared Lynn Randall
  • Patent number: 10238665
    Abstract: Disclosed herein are methods of treating fungal infections in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: March 26, 2019
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Carl Genberg, Chad S. Beus, Paul B. Savage
  • Publication number: 20190076581
    Abstract: This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.
    Type: Application
    Filed: November 8, 2018
    Publication date: March 14, 2019
    Inventors: Paul B. Savage, Carl Genberg, Ronald Bracken
  • Patent number: 10227376
    Abstract: The disclosure provides compounds, methods, and kits for diagnosis, detection, screening, and imaging of a disease condition (e.g., infection, cancer, tumor, neoplasia), in vitro, ex vivo, and/or in vivo. Certain embodiments include administering a cationic steroid antimicrobial (a “CSA” or “ceragenin”), the CSA including a steroidal backbone and a heterocyclic ring separated from the steroidal backbone by at least 4 atoms (and up to 24 atoms or more), to a subject having or at risk of having a disease condition in an amount effective to diagnose, detect, screen for or image the disease condition in the subject.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: March 12, 2019
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventor: Paul B. Savage
  • Patent number: 10226550
    Abstract: This disclosure relates to dermal treatment compositions, such as dermal fillers and tissue glues, and injectable compositions that incorporate one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the dermal treatment compositions to provide effective antimicrobial, anti-inflammatory, analgesic, anti-swelling and/or tissue-healing properties. A treatment composition includes a component formed from a biologically compatible material suitable for injection into and/or application onto tissue at a treatment site. One or more CSA compounds are mixed with the biologically compatible material so that the one or more CSA compounds are incorporated within the composition, forming a reservoir of CSA compounds within the resulting bolus of the treatment composition after injection and/or application.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: March 12, 2019
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Paul B. Savage, Carl Genberg, Ronald Bracken
  • Patent number: 10220045
    Abstract: Compositions and methods for preparing stabilized CSA compositions having reduced agglomeration and increased stability. The compositions have increased efficacy in killing microbes and reduced cytotoxicity to mammals. The compositions include a liquid carrier, micelles formed from an amphiphilic material, and CSA molecules encapsulated by the micelles. The CSA compositions can be formed by blending together a solvent or liquid carrier, a plurality of CSA molecules, and a micelle-forming agent and causing or allowing the micelle-forming agent to form micelles encapsulating at least a portion of the CSA molecules so that no more than 25% of the CSA molecules form agglomerates larger than 1 ?m in size. The CSA compositions can be used to treat mammals, such as mammals suffering from microbial diseases or infections.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: March 5, 2019
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Benjamin J. Darien, Paul B. Savage
  • Patent number: 10195215
    Abstract: Disclosed herein are methods of treating cancer and/or reducing cellular proliferation in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: February 5, 2019
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Carl Genberg, Paul B. Savage
  • Patent number: 10155788
    Abstract: Prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, or polymorphs thereof include a pharmaceutically and/or diagnostically active cationic steroidal antimicrobial (hereinafter “CSA”) compound or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof, and one or more cleavable groups (C.G.). Some embodiments include a CSA compound prepared in an inactive or less active form and that is capable of conversion to a fully active form upon administration to a subject, upon preparation of a pharmaceutical formulation containing the CSA composition, and/or upon exposure to physiological conditions. Pharmaceutical compositions include the prodrug or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof and one or more pharmaceutically acceptable excipients.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: December 18, 2018
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventor: Paul B. Savage